{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T07:20:56Z","timestamp":1767252056092,"version":"3.48.0"},"reference-count":18,"publisher":"The Royal Society","issue":"1579","license":[{"start":{"date-parts":[[2011,10,12]],"date-time":"2011-10-12T00:00:00Z","timestamp":1318377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/royalsociety.org\/journals\/ethics-policies\/data-sharing-mining\/"}],"content-domain":{"domain":["royalsocietypublishing.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,10,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Increased international support for both research into new vaccines and their deployment in developing countries has been evident over the past decade. In particular, the GAVI Alliance has had a major impact in increasing uptake of the six common infant vaccines as well as those against hepatitis B and yellow fever. It further aims to introduce pneumococcal and rotavirus vaccines in the near future and several others, including those against human papillomavirus, meningococcal disease, rubella and typhoid not long after that. In addition, there is advanced research into vaccines against malaria, HIV\/AIDS and tuberculosis. By 2030, we may have about 20 vaccines that need to be used in the developing world. Finding the requisite funds to achieve this will pose a major problem. A second and urgent question is how to complete the job of global polio eradication. The new strategic plan calls for completion by 2013, but both pre-eradication and post-eradication challenges remain. Vaccines will eventually become available beyond the field of infectious diseases. Much interesting work is being done in both autoimmunity and cancer. Cutting across disease groupings, there are issues in methods of delivery and new adjuvant formulations.<\/jats:p>","DOI":"10.1098\/rstb.2011.0093","type":"journal-article","created":{"date-parts":[[2011,9,5]],"date-time":"2011-09-05T03:34:38Z","timestamp":1315193678000},"page":"2833-2840","update-policy":"https:\/\/doi.org\/10.1098\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Vaccines and future global health needs"],"prefix":"10.1098","volume":"366","author":[{"given":"G. J. V.","family":"Nossal","sequence":"first","affiliation":[{"name":"The University of Melbourne ,","place":["Australia"],"department":["Department of Pathology"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"175","reference":[{"key":"2026010102182650000_RSTB20110093C1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1046\/j.0818-9641.2002.01139.x","article-title":"Gates, GAVI, the glorious global funds and more: all you ever wanted to know","volume":"81","author":"Nossal,","year":"2003","journal-title":"Immunol. Cell Biol."},{"key":"2026010102182650000_RSTB20110093C2","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1098\/rstb.2011.0075","article-title":"Twenty-first century vaccines","volume":"366","author":"Rappuoli,","year":"2011","journal-title":"Phil. Trans. R. Soc. B"},{"key":"2026010102182650000_RSTB20110093C3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/00006454-198906000-00010","article-title":"Typhoid vaccines come of age","volume":"8","author":"Levine,","year":"1989","journal-title":"Pediatr. Infect. Dis. J."},{"key":"2026010102182650000_RSTB20110093C4","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa0807381","article-title":"Efficacy of RTS,S\/AS01E vaccine against malaria in children 5 to 17 months of age","volume":"359","author":"Bejon,","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"2026010102182650000_RSTB20110093C5","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ijpara.2010.04.008","article-title":"Merozoite surface proteins of the malaria parasite: the MSP1 complex and the MSP7 family","volume":"40","author":"Kadekoppala,","year":"2010","journal-title":"Int. J. Parasitol."},{"key":"2026010102182650000_RSTB20110093C6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/nature00937","article-title":"Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria","volume":"418","author":"Schofield,","year":"2002","journal-title":"Nature"},{"key":"2026010102182650000_RSTB20110093C7","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1086\/339409","article-title":"Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites","volume":"185","author":"Hoffmann,","year":"2002","journal-title":"J. Infect. Dis."},{"key":"2026010102182650000_RSTB20110093C8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4161\/hv.6.1.9654","article-title":"Genetically engineered, attenuated whole-cell vaccine approaches for malaria","volume":"6","author":"Vaughan,","year":"2010","journal-title":"Hum. Vaccin."},{"key":"2026010102182650000_RSTB20110093C9","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S0140-6736(02)09784-2","article-title":"Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum","volume":"360","author":"Pombo,","year":"2002","journal-title":"Lancet"},{"key":"2026010102182650000_RSTB20110093C10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1056\/NEJMoa0904797","article-title":"Effect of human rotavirus vaccine on severe diarrhea in African infants","volume":"362","author":"Madhi,","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2026010102182650000_RSTB20110093C11","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm,","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"2026010102182650000_RSTB20110093C12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.coi.2010.04.006","article-title":"Novel tuberculosis vaccines on the horizon","volume":"22","author":"Parida,","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"2026010102182650000_RSTB20110093C13","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.ijpara.2010.05.001","article-title":"Eradication of Taenia solium cysticercosis: a role for vaccination of pigs","volume":"40","author":"Lightowlers,","year":"2010","journal-title":"Int. J. Parasitol."},{"key":"2026010102182650000_RSTB20110093C14","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.vaccine.2010.10.026","article-title":"Economic analysis of the global polio eradication initiative","volume":"29","author":"Duintjer Tebbens,","year":"2010","journal-title":"Vaccine"},{"key":"2026010102182650000_RSTB20110093C15","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1098\/rstb.2011.0103","article-title":"Therapeutic vaccines for chronic diseases: successes and technical challenges","volume":"366","author":"Bachmann,","year":"2011","journal-title":"Phil. Trans. R. Soc. B"},{"key":"2026010102182650000_RSTB20110093C16","first-page":"969","article-title":"Vaccination for autoimmune and other chronic inflammatory disorders","volume-title":"New generation vaccines","author":"Harrison,","edition":"4th edn"},{"key":"2026010102182650000_RSTB20110093C17","doi-asserted-by":"crossref","first-page":"41ra51","DOI":"10.1126\/scitranslmed.3001012","article-title":"Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease","volume":"2","author":"Tye-Din,","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"2026010102182650000_RSTB20110093C18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/PPO.0b013e3181a7450f","article-title":"Recent advances using anti-CTLA-4 for the treatment of melanoma","volume":"15","author":"Sarnaik,","year":"2009","journal-title":"Cancer J."}],"container-title":["Philosophical Transactions of the Royal Society B: Biological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/royalsocietypublishing.org\/doi\/pdf\/10.1098\/rstb.2011.0093","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/royalsocietypublishing.org\/doi\/full-xml\/10.1098\/rstb.2011.0093","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article-pdf\/366\/1579\/2833\/100596\/rstb.2011.0093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article-pdf\/366\/1579\/2833\/100596\/rstb.2011.0093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T07:18:33Z","timestamp":1767251913000},"score":1,"resource":{"primary":{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article\/366\/1579\/2833\/21663\/Vaccines-and-future-global-health-needsVaccines"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,12]]},"references-count":18,"journal-issue":{"issue":"1579","published-print":{"date-parts":[[2011,10,12]]}},"URL":"https:\/\/doi.org\/10.1098\/rstb.2011.0093","relation":{},"ISSN":["0962-8436","1471-2970"],"issn-type":[{"type":"print","value":"0962-8436"},{"type":"electronic","value":"1471-2970"}],"subject":[],"published":{"date-parts":[[2011,10,12]]},"assertion":[{"value":"2011-10-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}